Background: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction with PAI-1 level. Opium addiction i...

The aim of the study is to assess the diagnostic accuracy of some fibrinolytic parameters in the differential diagnosis between patients with unstable angina (UA) and musculoskeletal disorders (MSD). Methods. This cross-sectional study included 119 patients with chest pain (CP) and provisional diagnosis “UA”. After a full set of diagnostic procedures, authors formed 4 groups: patients with isc...

results a total of 46 patients participated in this study. the significant differences between recovering patients and the patients who died, regarding aspartate aminotransferase (ast), creatine phosphokinase (cpk), lactate dehydrogenase (ldh), prothrombin time (pt), activated partial thromboplastin time (aptt), and thrombocyte and fibrinogen levels, were consistent with many clinical studies i...

Background: To analyze the correlations between plasma coagulation factor VII (FVII), plasminogen activator inhibitor-1 (PAI-1), uric acid, and insulin resistance (IR) diabetic macroangiopathy (DMAP) in elderly patients with type 2 diabetes mellitus (T2DM).

Many cancer cell lines and cancers overexpress receptor bound urokinase plasminogen activator on the cell surface. The urokinase plasminogen activator bound to its receptor remains on the cell surface for a prolonged period of time. When urokinase plasminogen activator/urokinase plasminogen activator receptor complex binds plasminogen activator inhibitor (PAI-1), the inhibitor triggers a series...

background: recurrent pregnancy loss (rpl) defined by two or more failed pregnancies before 20 weeks of gestation. several factors play a role in rpl including thrombophilic conditions which can be influenced by gene polymorphisms. plasminogen activator inhibitor-1 (pai-1) and angiotensin converting enzyme (ace) genes are closely related to fibrinolytic process, embryonic development and pregna...

Plasminogen activator inhibitor-I (PAI-I) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-I plays an important role in cardiovascular diseases (mainly through inhibition of t-PA), and in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vi...

Patients with defective plasminogen activator inhibitor protein (PAI-1) or with PAI-1 deficiency can experience hemorrhage as a result of a hyperfibrinolysis. In these patients, a normal thrombus forms, but endogenous lysis is unchecked as tissue plasminogen activator is unopposed. Treatment includes anti-fibrinolytic agents, including oral tranexamic acid. Another treatment option is the admin...

Introduction: In this study, coagulation and fibrinolysis parameters their association with disease severity were investigated in coronavirus (COVID-19) patients. Materials Methods: COVID-19 patients (n = 446) admitted to our institute between 21 February 2021 17 March 2022, recruited. Clinical data staging collected from all Blood samples analyzed for several of coagulation, including alpha-2-...